A

Apellis Pharmaceuticals
D

APLS

21.390
USD
-0.68
(-3.06%)
مغلق
حجم التداول
97,852
الربح لكل سهم
-1
العائد الربحي
-
P/E
59
حجم السوق
2,706,374,413
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ 5 أشهر
buy
2025-09-03 03:40
APLS Chart
المزيد
أصول ذات صلة المقالات

العنوان: Apellis Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).